Cargando…

Transcatheter Aortic Valve Implantation: Bahrain Experience

BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure that is considered a good alternative to surgical aortic valve replacement (sAVR) in selected patients. Our aim is to determine the baseline, procedural characteristics and one-year clinical outcomes of our...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousif, Nooraldaem, Subbramaniyam, Suddharsan, Thevan, Babu, Amin, Mohammad, Sulaibikh, Leena, Bukamal, Nazar, Tareif, Habib, Shivappa, Sadananda, Amin, Haitham, Noor, Husam A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Heart Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721461/
https://www.ncbi.nlm.nih.gov/pubmed/33299788
http://dx.doi.org/10.37616/2212-5043.1143
_version_ 1783620025795477504
author Yousif, Nooraldaem
Subbramaniyam, Suddharsan
Thevan, Babu
Amin, Mohammad
Sulaibikh, Leena
Bukamal, Nazar
Tareif, Habib
Shivappa, Sadananda
Amin, Haitham
Noor, Husam A.
author_facet Yousif, Nooraldaem
Subbramaniyam, Suddharsan
Thevan, Babu
Amin, Mohammad
Sulaibikh, Leena
Bukamal, Nazar
Tareif, Habib
Shivappa, Sadananda
Amin, Haitham
Noor, Husam A.
author_sort Yousif, Nooraldaem
collection PubMed
description BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure that is considered a good alternative to surgical aortic valve replacement (sAVR) in selected patients. Our aim is to determine the baseline, procedural characteristics and one-year clinical outcomes of our TAVI registry. METHODS: This study is a retrospective observational analysis of a prospectively designed cohort comprising 81 consecutive patients treated at Mohammed bin Khalifa Cardiac Centre (MKCC) who were enrolled in Bahrain TAVI registry from February 2014 to February 2019. The clinical endpoints were defined according to the updated Valve Academic Research Consortium-2 (VARC-2) consensus document. RESULTS: Out of the 81 patients included in our study, there were 37 (45.7%) males. The mean age was 76.4 ± 8.9 years with a mean Logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE II) of 4.1 ± 2.5 and a mean Society of Thoracic Surgery (STS) Risk Score of 4.2 ± 3.5. Evolute-R valve was used for 36 (44.4%) patients, Edward Sapien for 26 patients (32.1%), and Core valve for 19 patients (23.5%). At one year follow up, all-cause death was reported in three (3.7%) patients; none of them was cardiovascular mortality. As per VARC-II criteria, no cases fulfilled the criteria of valve dysfunction but TAVI-related complications (i.e., TAV-in-TAV deployment) were reported in four (4.9%) cases. One (1.2%) case of major bleeding was encountered but no patient experienced life-threatening bleeding. Major vascular complications were documented in two patients (2.5%) only. Significant Acute Kidney Injury (AKI) occurred in two (2.5%) patients, both classified as stage-2 but no one deteriorated to stage-3 or hemodialysis. Seven (8.6%) patients required permanent pacemakers, and all were implanted during the index admission for TAVI. One patient (1.2%) had stroke and all survivors completed one-year follow up. CONCLUSION: The TAVI program in Bahrain is encouraging and corresponds to the finest international centers outcomes in terms of procedural success and complications rate.
format Online
Article
Text
id pubmed-7721461
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Saudi Heart Association
record_format MEDLINE/PubMed
spelling pubmed-77214612020-12-08 Transcatheter Aortic Valve Implantation: Bahrain Experience Yousif, Nooraldaem Subbramaniyam, Suddharsan Thevan, Babu Amin, Mohammad Sulaibikh, Leena Bukamal, Nazar Tareif, Habib Shivappa, Sadananda Amin, Haitham Noor, Husam A. J Saudi Heart Assoc Original Article BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure that is considered a good alternative to surgical aortic valve replacement (sAVR) in selected patients. Our aim is to determine the baseline, procedural characteristics and one-year clinical outcomes of our TAVI registry. METHODS: This study is a retrospective observational analysis of a prospectively designed cohort comprising 81 consecutive patients treated at Mohammed bin Khalifa Cardiac Centre (MKCC) who were enrolled in Bahrain TAVI registry from February 2014 to February 2019. The clinical endpoints were defined according to the updated Valve Academic Research Consortium-2 (VARC-2) consensus document. RESULTS: Out of the 81 patients included in our study, there were 37 (45.7%) males. The mean age was 76.4 ± 8.9 years with a mean Logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE II) of 4.1 ± 2.5 and a mean Society of Thoracic Surgery (STS) Risk Score of 4.2 ± 3.5. Evolute-R valve was used for 36 (44.4%) patients, Edward Sapien for 26 patients (32.1%), and Core valve for 19 patients (23.5%). At one year follow up, all-cause death was reported in three (3.7%) patients; none of them was cardiovascular mortality. As per VARC-II criteria, no cases fulfilled the criteria of valve dysfunction but TAVI-related complications (i.e., TAV-in-TAV deployment) were reported in four (4.9%) cases. One (1.2%) case of major bleeding was encountered but no patient experienced life-threatening bleeding. Major vascular complications were documented in two patients (2.5%) only. Significant Acute Kidney Injury (AKI) occurred in two (2.5%) patients, both classified as stage-2 but no one deteriorated to stage-3 or hemodialysis. Seven (8.6%) patients required permanent pacemakers, and all were implanted during the index admission for TAVI. One patient (1.2%) had stroke and all survivors completed one-year follow up. CONCLUSION: The TAVI program in Bahrain is encouraging and corresponds to the finest international centers outcomes in terms of procedural success and complications rate. Saudi Heart Association 2020-10-14 /pmc/articles/PMC7721461/ /pubmed/33299788 http://dx.doi.org/10.37616/2212-5043.1143 Text en © 2020 Saudi Heart Association This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Yousif, Nooraldaem
Subbramaniyam, Suddharsan
Thevan, Babu
Amin, Mohammad
Sulaibikh, Leena
Bukamal, Nazar
Tareif, Habib
Shivappa, Sadananda
Amin, Haitham
Noor, Husam A.
Transcatheter Aortic Valve Implantation: Bahrain Experience
title Transcatheter Aortic Valve Implantation: Bahrain Experience
title_full Transcatheter Aortic Valve Implantation: Bahrain Experience
title_fullStr Transcatheter Aortic Valve Implantation: Bahrain Experience
title_full_unstemmed Transcatheter Aortic Valve Implantation: Bahrain Experience
title_short Transcatheter Aortic Valve Implantation: Bahrain Experience
title_sort transcatheter aortic valve implantation: bahrain experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721461/
https://www.ncbi.nlm.nih.gov/pubmed/33299788
http://dx.doi.org/10.37616/2212-5043.1143
work_keys_str_mv AT yousifnooraldaem transcatheteraorticvalveimplantationbahrainexperience
AT subbramaniyamsuddharsan transcatheteraorticvalveimplantationbahrainexperience
AT thevanbabu transcatheteraorticvalveimplantationbahrainexperience
AT aminmohammad transcatheteraorticvalveimplantationbahrainexperience
AT sulaibikhleena transcatheteraorticvalveimplantationbahrainexperience
AT bukamalnazar transcatheteraorticvalveimplantationbahrainexperience
AT tareifhabib transcatheteraorticvalveimplantationbahrainexperience
AT shivappasadananda transcatheteraorticvalveimplantationbahrainexperience
AT aminhaitham transcatheteraorticvalveimplantationbahrainexperience
AT noorhusama transcatheteraorticvalveimplantationbahrainexperience